USANA Health Sciences (USNA) Misses Q4 EPS by 16c; Issues Light FY16 Outlook
USANA Health Sciences (NYSE: USNA) reported Q4 EPS of $1.83, $0.16 worse than the analyst estimate of $1.99. Revenue for the quarter came in at $232.6 million versus the consensus estimate of $238.91 million.
GUIDANCE:
USANA Health Sciences sees FY2016 EPS of $7.60-$8.15, versus the consensus of $8.59. USANA Health Sciences sees FY2016 revenue of $1.02-1.05 billion, versus the consensus of $1.02 billion.
For earnings history and earnings-related data on USANA Health Sciences (USNA) click here.
